Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Janssen's UPTRAVI IV FDA-Approved for PAH | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Janssen’s UPTRAVI IV FDA-Approved for PAH

New therapeutic option allows patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The Janssen Pharmaceutical Companies of Johnson & Johnson received approval from the FDA for UPTRAVI (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy. UPTRAVI IV is a therapeutic option that will allow patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy, as uninterrupted treatment is considered key for individuals with PAH. UPTRAVI® tablets were first approved by the FDA in 2015 to delay disease progression and reduce the risk of hospitalization for PAH.
 
The approval is based upon the findings from a prospective, multi-center, open-label single sequence cross-over Phase 3 study designed to assess the safety, tolerability and pharmacokinetics of temporarily switching between UPTRAVI tablets and UPTRAVI IV.
 
The UPTRAVI IV study enrolled 20 patients who received all UPTRAVI doses (either tablets or IV). The study found that the switch between UPTRAVI tablets and UPTRAVI IV was well tolerated with no unexpected safety findings.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters